SPRY Overview

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Wall Street analysts forecast SPRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRY is32.50 USD with a low forecast of 30.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

ARS Pharmaceuticals Inc revenue for the last quarter amounts to 28.09M USD, decreased -67.56

ARS Pharmaceuticals Inc. EPS for the last quarter amounts to -0.42 USD, decreased -200.00

ARS Pharmaceuticals Inc (SPRY) has 158 emplpoyees as of March 27 2026.

Today SPRY has the market capitalization of 849.98M USD.